← Leaderboards
Kathleen Mulvaney
Broad Institute, Inc.
$1,014,016
Attributed
$1,014,016
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $396.4K · FY2018–25$500K$375K$250K$125K$0
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$1,014,016 · 2
By mechanism
R35$792,583 · 1
F32$221,433 · 1
Top collaborators
No co-investigators on record.
Most similar at Broad Institute, Inc.
Same institution · by research overlap
- Catherine Ju-Ying Wu$43,266,044
Others in their field
Other Emerging Leaders on “Methylation”
- Leigh A Johnson · University Of North Texas Hlth Sci Ctr$15,987,064
- Stacey Lynn Clardy · Utah State Higher Education System--University Of Utah$15,093,619
- Sonia Minikel Vallabh · Broad Institute, Inc.$15,007,691
- Leonard Freedman · Leidos Biomedical Research, Inc.$13,879,565
- Michael-Christopher Keogh · Epicypher, Inc.$12,073,306
- Chongyuan Luo · University Of California Los Angeles$9,805,856
Research focus
MethylationProteinsResearch ProposalsChromatinTherapeutic TargetEnzymesMessenger RnaMalignant NeoplasmsMethyltransferaseRecruitRna SplicingSiteBindingGenetic TranscriptionArginineCell PhysiologyCellsBinding SitesBiologyFamilyCdkn2a GeneCatalytic DomainCancer TypeComplex
Grant awards (6)
Resolving cellular functions of arginine methylation$396,203
R35 · FY2025 · GM · contact PI
Resolving cellular functions of arginine methylation$396,380
R35 · FY2024 · GM · contact PI
The novel PRMT5-substrate adaptor interface provides a therapeutic target in MTAP null tumors$33,723
F32 · FY2021 · CA · contact PI
The novel PRMT5-substrate adaptor interface provides a therapeutic target in MTAP null tumors$67,446
F32 · FY2020 · CA · contact PI
The novel PRMT5-substrate adaptor interface provides a therapeutic target in MTAP null tumors$61,610
F32 · FY2019 · CA · contact PI
The novel PRMT5-substrate adaptor interface provides a therapeutic target in MTAP null tumors$58,654
F32 · FY2018 · CA · contact PI